Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Paclitaxel in HER2+ Trastuzumab-Refractory Esophagogastric Cancer
NCT01522768Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2012
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in esophageal cancer, gastric cancer (GC), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2012; status: completed.
02
Drugs
afatinib
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT01522768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522768.